Objective 
Introduction:
In ageing population, the absolute number of deaths due to cardiovascular disease in women is actually increasing. The risk factors for coronary heart disease in women are cigarette, smoking, hypertension, (including isolated systolic hypertension), dyslipidemia, diabetes mellitus, obesity, sedentary lifestyle, and poor nutrition. Although most risk factors for coronary heart disease are similar in men and women, gender differences have been documented, particularly diabetes and dyslipidemia. Patients with chronic kidney disease (CKD) have high burden of cardiovascular morbidity and mortality. Once patients reach end stage kidney disease (CKD stage -5) and enter dialysis programs, they have an alarmingly high rate of cardiovascular death with those in the youngest age range of 25 years having equivalent cardiovascular mortality rate of 75 to 85 year olds in the general population. 1 End stage renal disease (ESRD) is associated with accelerated atherosclerosis and premature death from cardiovascular disease. These events are driven by oxidative stress inflammation and lipid disorders. ESRDinduced lipid abnormalities primarily stem from dysregulation of high density lipoprotein (HDL), triglyceride-rich lipoprotein metabolism, and oxidative modification of lipoprotein. 2 Hypertriglyceridemia, abnormal composition, and impaired clearance of triglyceride-rich lipoproteins and their remnants are mediated by down-regulation of lipoprotein lipase, hepatic lipase, very low density lipoprotein (VLDL) receptor, and LDL receptor-related protein, relative reduction in Apo C-II/Apo C-III ratio, up-regulation of acyl-COA cholesterol acyl transferase, and elevated plasma level J MEDICINE 2015; 16 : 14-17 . of cholesterol ester-poor prebeta HDL. The vast majority of patients with chronic kidney disease does not progress to end-stage renal failure but do have a significantly higher incidence of cardiovascular co-morbidities. 3 Abnormal lipid metabolism in chronic renal failure is attributed to hormonal influence. Akmalet al 4 stated that excess parathyroid hormone (PTH) adversely affect lipid metabolism in CRF. In their study, they observed that excess blood level of PTH and not other consequences of CRF are mainly responsible for the abnormalities in lipid metabolism, because excess PTH reduces post-heparin lipoprotein lipase (LPL) activity in plasma, which in turn results in impaired lipid removal from the circulation and consequently hyperlipidemia. Lee et al 5 suggested from their study that low lysophosphatidylcholine, but not oxidixed LDL is associated with increased risk of CVD among a group of Korean haemodialysis patients.
Patients with abnormal kidney function are at a greatly increased risk of heart disease and subsequent death from cardiovascular causes. Manjunath et al 6 from their study demonstrated that certain levels of dyslipidemia were indecently associated with renal replacement therapy and rapid renal progression in CKD stage 3-5. Multidetector computed tomographic angiography showed that mild and moderate pre-dialysis CKD are independent risk factors for coronary artery atherosclerosis. 7 Cholesterol (one of the major lipid in lipoprotein) is both the substrate for, and the target of the steroidal sex hormones. 8 It is on this premise that this study is carried out to investigate the development of cardiovascular disease in chronic renal failure among female gender.
Materials and methods:
A total of 40 adult female subjects were used in this study. 20 of them were apparently healthy females (control group), while the rest 20 were patients with chronic renal failure on dialysis treatment in Nigeria (CRF group). 5ml of blood sample collected from each subjects at fasting state (in the morning) was used to estimate the level of serum Total Cholesterol (TC), Triglyceride (TG), HDL-C, LDL-C, and VLDL-C using enzymatic method with Human Diagnostic test kit. 9 The blood sample was collected after obtaining informed consent from the participants and Hospital management.
Statistical analysis:
The data collected after biochemical analysis was subjected to statistical calculation using statistical software (Megastat). The mean, standard deviation/ standard error of mean (s.e), F-distribution test were obtained. Critical value or test of probability less than 0.05 (p< 0.05) was regarded significant.
Results:
The lipid profiles of the chronic renal failure patients (TC 5.70±0.80mmol/l, TG 1.46±0.40mmol/l HDL-C 1.40±0.2mmol/ l, LDL-C 3.50±0.2mmol/l, and VLDL-C 0.67±0.2mmol/l), as shown in Table 1 , were significantly (p<0.05) altered when compared with those of the healthy subjects (TC 4.03±0.13mmol/l, TG 1.10± 0.3mmol/l, HDL-C 1.70± 0.04mmol/ l, LDL-C 1.85±0.5mmol/l, and VLDL-C 0.50± 0.01mmol/l). The cardiovascular risk indices, TC/HDL-C and LDL-C/HDL-C, of the chronic renal failure patients (TC/HDL-C 3.91±0.24 and LDL-C/HDL-C 2.50±0.01) as shown in Table 2 , were significantly higher (p<0.05) than those of the healthy subjects (TC/HDL-C 2.40±0.09, LDL-C/HDL-C 1.10±0.08).
In figure 1 and 2 , there was no difference in the percentage of VLDL-C& TG in circulation between the control (VLDL -C 5% and TG 45%) and chronic renal failure patients (VLDL -C 5% and TG 44%).
Total cholesterol (TC) and other cholesterol-rich lipoproteins (HDL-C and LDL-C) of the renal failure patients (TC 5.70±0.80mmol/l, HDL-C 1.40±0.2mmol/lm and LDL-C 3.50±0.2mmol/l) showed a significant difference (p<0.05) in plasma concentration (in mmol/l) than that of the healthy females (TC 4.03±0.13mmol/l, HDL-C 1.70± 0.04mmol/l and LDL-C 1.85±0.5mmol/l). It was observed in this study that 45% of Total plasma lipid (12.73mmol/l) was Total Cholesterol (TC) in renal failure patients while 44% of Total plasma lipid (9.18mmol/l) was Total cholesterol in the healthy females.Going by the percentage level of TC, there was no significant difference (p>0.05). HDL-C and LDL-C levels of the renal failure patients showed a great differencein percentage (HDL-C 11% and LDL-C 27%) than that of the healthy females (HDL-C 19% and LDL-C 20%). This showed that in CRF, despite high level of Total plasma lipid (12.73mmol/l), lower percentage of HDL-C and higher percentage of LDL-C were in circulation unlike the healthy patients (total plasma lipid 9.18 mmol/l) with higher percentage of HDL-C and lower percentage of LDL-C in circulation. This indicated that in CRF, there was development of atherosclerosis/CVD. Vaziri 2 stated that ESRD-induced lipid abnormalities primarily stem from dysregulation of HDL-C, TG-rich lipoprotein metabolism, and oxidative modification of lipoprotein. Significant higher levels of TC/HDL-C and LDL-C/HDL-C ratio in CRF patients also indicated that development of CVD or atherosclerosis in CRF patients. Akmalet al 4 stated excess parathyroid hormone (PTH) in CRF adversely affects lipid metabolism. They stated that excess PTH reduces post heparin lipoprotein lipase activity in plasma which in turn results in impaired lipid removal from the circulation. High level of LDL-C and low HDL-C are implicated in development of atherosclerotic CVD 11, 12 and the higher the ratio of LDL-C to HDL-C the higher the risk of developing CVD.
In conclusion, women with chronic renal failure (on dialysis treatment) develop atherosclerotic cardiovascular disease.
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Discussion:
It was observed in this study that the percentage composition of lipid parametersas shown in figure1 and 2 indicated no difference in percentage of plasma TG and VLDL-C components in circulation though the concentrations of these parameters (in mmol/l) showed a significant higher level (p<0.05) in CRF patients than that of the control subjects. This finding indicated that relative percentage of TG and VLDL-C in circulation among female patients on dialysis would not give a clear metabolic effect of renal failure on these parameters and secondly, it showed that transportation of these lipids in plasma are of equal percentage irrespective of the renal damage.This abnormality in TG and TG-rich lipoprotein stems from dysregulation of these lipid and oxidative modification of lipoprotein. 2 Eknoyan 10 said that the reduced catabolism of lipoprotein that are rich in TG is an early fundamental disturbance of lipoprotein metabolism in renal disease, but clinical evidence suggests that this is not necessarily linked to increased plasma concentration of TG. 
